KR101343819B1 - The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food - Google Patents
The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food Download PDFInfo
- Publication number
- KR101343819B1 KR101343819B1 KR1020130037319A KR20130037319A KR101343819B1 KR 101343819 B1 KR101343819 B1 KR 101343819B1 KR 1020130037319 A KR1020130037319 A KR 1020130037319A KR 20130037319 A KR20130037319 A KR 20130037319A KR 101343819 B1 KR101343819 B1 KR 101343819B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- red ginseng
- ginsenosides
- obesity
- composition
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 75
- 239000000843 powder Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 27
- 230000002180 anti-stress Effects 0.000 title claims abstract description 27
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 19
- 239000011707 mineral Substances 0.000 title claims abstract description 19
- 229940088594 vitamin Drugs 0.000 title claims abstract description 19
- 229930003231 vitamin Natural products 0.000 title claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 19
- 239000011782 vitamin Substances 0.000 title claims abstract description 19
- 235000013376 functional food Nutrition 0.000 title abstract description 9
- 230000036541 health Effects 0.000 title abstract description 9
- 239000012141 concentrate Substances 0.000 claims abstract description 48
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 45
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 229910052702 rhenium Inorganic materials 0.000 claims abstract description 3
- 235000010755 mineral Nutrition 0.000 claims description 16
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 229940089161 ginsenoside Drugs 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- -1 2 to 2% by weight Chemical compound 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 15
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 abstract description 2
- 235000008504 concentrate Nutrition 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 33
- 240000004371 Panax ginseng Species 0.000 description 24
- 238000012360 testing method Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229960002297 fenofibrate Drugs 0.000 description 5
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 5
- 231100000304 hepatotoxicity Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 210000000579 abdominal fat Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 2
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 2
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 2
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- AVXFIVJSCUOFNT-QXPABTKOSA-N ginsenoside Rk3 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1 AVXFIVJSCUOFNT-QXPABTKOSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- OZTXYFOXQFKYRP-RISAHGKBSA-N Ginsenoside Rh4 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1 OZTXYFOXQFKYRP-RISAHGKBSA-N 0.000 description 1
- OZTXYFOXQFKYRP-TXRYYSRHSA-N Ginsenoside Rh4 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZTXYFOXQFKYRP-TXRYYSRHSA-N 0.000 description 1
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- SHUCWEWLEVIHGP-UHFFFAOYSA-N [Fe].[I] Chemical compound [Fe].[I] SHUCWEWLEVIHGP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 11종의 진세노사이드 성분을 유효성분으로 하는 홍삼농축액 분말과 비타민 및 미네랄로 조성되는 항스트레스, 항고지혈증 및 항비만용 조성물 및 이를 이용한 건강기능식품에 관한 것이다. The present invention relates to an anti-stress, anti-hyperlipidemia and anti-obesity composition comprising red ginseng concentrate powder containing 11 kinds of ginsenosides as an active ingredient, vitamins and minerals, and health functional foods using the same.
현대사회에서 심각하게 대두되고 있는 항스트레스 및 대사성 질환은 질환으로 판명받은 환자뿐만 아니라 많은 일반인들도 겪고 있는 증상이며, 이에 대한 치료를 위하여 Monoamine oxidase, 선택적 세로토닌 재흡수 억제제, 항고지혈증 및 항비만용제제와 같은 제제들은 치료효과와 더불어 부작용들이 보고되어 있으며, 아직까지 부작용이 적으면서도 우수한 효과를 발휘하는 예방 또는 치료목적의 건강기능식품의 소재에 대한 연구와 개발이 많지 않으므로 약물의 형태가 아닌 식품으로써 스트레스와 항고지혈증 및 항비만용을 예방하거나 개선시킬 수 있는 제품의 개발이 절실히 요구되고 있다.Antistress and metabolic diseases, which are seriously emerging in modern society, are a symptom suffered by many people as well as patients who have been identified as diseases, and monoamine oxidase, selective serotonin reuptake inhibitors, anti-hyperlipidemia and anti-obesity agents for treatment Drugs such as drugs have reported side effects as well as therapeutic effects, and there are few researches and developments on the material of preventive or therapeutic health functional foods that have excellent side effects with little side effects. Therefore, there is an urgent need for the development of products that can prevent or improve stress, anti-hyperlipidemia and anti-obesity.
특히 약용식물이나 천연물을 이용한 조성물 개발에 대한 관심이 고조되어 있으며, 이러한 천연물의 형태 중 가능성 있는 물질로 홍삼, 비타민류 및 미네랄류에 관심을 갖고 본 발명에 대한 연구와 개발을 하기에 이르렀다.In particular, interest in the development of compositions using medicinal plants or natural products is increasing, and as a possible substance in the form of such natural products, the interest in red ginseng, vitamins and minerals has led to the research and development of the present invention.
인삼은 식물학적으로 오가과(Araliaceae), 인삼속(Panax)에 속하는 식물로서, 수삼을 증숙, 건조 및 가공처리 하여 제조된 홍삼과 함께 수천년 동안 신비의 명약으로 애용되어 왔으며, 최근에는 약리효능성분인 진세노사이드 종류별 효능의 우수성이 과학적으로 속속들이 밝혀지고 있는 실정이다. Ginseng is botanically belonging to the genus Araliaceae, Panax ginseng, and has been used as a mysterious medicine for thousands of years along with red ginseng prepared by steaming, drying and processing fresh ginseng. The superiority of ginsenoside types of efficacy is being discovered scientifically one after another.
고려인삼의 약리효능으로는 중추신경계질환, 항불안, 신경계, 마약중독해독 효능, 혈관작용, 알콜해독, 지질대사와 피로회복, 항당뇨, 고지혈증, 항바이러tm, 면역증강, 성기능 개선, 항암 및 암예방 효능 등이 있으며, 특히, 진세노사이드 Rb1으로 대표되는 panaxadiol(PD)계 사포닌은 중추신경에 대한 억제작용을 나타내어 정신안정, 신경이완, 진통, 항암, 항경련, 혈압강하 작용 등을 나타내며, 진세노사이드 Rg1으로 대표되는 panaxatriol(PT)계 사포닌은 중추신경에 대한 흥분적으로 작용하여, 항피로작용을 나타내는 것으로 알려지고, 더욱이, 개별 사포닌마다 그 약리효능이 각각 다르고 새로운 효능을 나타내는 것으로 보고되어 있으며[최신고려인삼연구, 고려인삼학회, 2007], 고려인삼 중의 진세사이드 종류 및 주요 진세노사이드의 효능은 아래 [표 1]에 나타내었다.The pharmacological effects of Korean ginseng include central nervous system disease, anti-anxiety, nervous system, drug addiction, vascular effect, alcohol detoxification, lipid metabolism and fatigue, antidiabetic, hyperlipidemia, antivirus tm, immunity enhancement, sexual function improvement, anticancer and In particular, panaxadiol (PD) -based saponins, represented by ginsenoside Rb 1 , have inhibitory effects on the central nervous system, which may lead to mental stability, nerve relaxation, analgesia, anticancer, anticonvulsion, and blood pressure lowering effects. Panaxatriol (PT) -based saponins, represented by ginsenoside Rg 1 , are known to exert an anti-fatigue effect on the central nervous system. Moreover, the pharmacological efficacy of each saponin is different and new efficacy is shown. The latest Korean ginseng research, Korea Ginseng Society, 2007], the types of ginsenosides and major ginsenosides of Korean ginseng are shown in Table 1 below. Burned out.
또 아래 [표 2]에 나타낸 바와 같이 고려인삼에는 약 22종의 진세노사이드가 포함되어 있으며 고려인삼에 함유된 진세노사이드의 종류는 전칠삼, 화기삼 등의 외국삼에 비해 2배이상 많은 종류의 진세노사이드를 함유하고 있는 특징으로 인하여 고려인삼이 외국삼에 비하여 효능이 훨씬 뛰어난 것으로 밝혀지고 있다. In addition, as shown in [Table 2], Korean ginseng contains about 22 kinds of ginsenosides, and the types of ginsenosides contained in Korean ginseng are more than twice as many as foreign ginsengs such as jeonchisam and hwagisam. Due to the feature of ginsenoside, Korean ginseng is found to be much more effective than foreign ginseng.
그리고 비타민류의 체내기능은 매우 광범위하며, 대부분은 효소나 또는 효소의 역할을 보조하는 조효소의 구성성분이 되어 탄수화물, 지방, 무기질의 대사에 관여한다. 생물체의 생명현상은 생체조직 내에서 일어나는 수 많은 연쇄적인 화학반응에 의하여 유지되며, 이 일련의 생화학반응에 직접 참여하는 물질이 아니므로 자신이 도움을 주는 화학반응에 의하여 완전히 소모되지 않으므로 비타민의 필요량은 매우 소량으로 충분하지만, 이 소량의 필요량이 공급되지 않을 때 생명현상의 유지에 필요한 체내 영양소의 대사가 지장을 받게 된다. 국내 건강기능식품공전에 대사성기능 활성효능이 있는 비타민류로는 비타민B1, 비타민B2, 비타민C, 비오틴, 엽산 등이 있다.In addition, vitamins have a wide range of body functions, and most of them are enzymes or coenzymes that support the role of enzymes and are involved in the metabolism of carbohydrates, fats and minerals. The life phenomena of organisms are maintained by a number of chain chemical reactions in the living tissue, and since they are not directly involved in this series of biochemical reactions, they are not consumed completely by the chemical reactions they support, so the required amount of vitamin Is very small, but when this small amount is not supplied, the metabolism of nutrients in the body needed to maintain life is hampered. Vitamins with metabolic activity in the health functional foods in Korea include vitamin B1, vitamin B2, vitamin C, biotin, folic acid.
또 미네랄류의 체내기능은 신체의 성장과 유지, 체내의 여러 생리기능 등을 조절 및 유지, 신경 자극의 전달, 근육 수축 각종 영양소의 생성과 기능 등이 있고, 뼈, 치아 등 신체의 구성 호르몬과 신진대사 관여 등 체내에서 중요한 역할을 하는 영양소로, 비록 신체의 3.5%~4%정도 밖에 존재하지 않지만 이 중 하나라도 부족하면 신체 전체의 균형이 깨지고 뒤흔들리게 된다. 국내 건강기능식품공전에 대사성기능 활성효능이 있는 미네랄류로는 셀레륨, 철, 요오드, 망간, 칼슘 및 마그네슘 등이 있다.In addition, the functions of minerals in the body include the growth and maintenance of the body, the regulation and maintenance of various physiological functions in the body, the transmission of nerve stimuli, the production and function of various nutrients in muscle contraction, and the constituent hormones and bone metabolism of the body such as bones and teeth. It is a nutrient that plays an important role in the body, such as metabolic involvement. Although it exists only about 3.5% to 4% of the body, lack of any of these will cause the whole body to be unbalanced and shaken. Minerals with metabolic activity in the health functional food industry in Korea include selenium, iron, iodine, manganese, calcium and magnesium.
상기 [표 2]에 나타낸 바와 같이 고려인삼에는 약 22종의 진세노사이드가 포함되어 있으며, 과학적으로 약 22종의 진세노사이드에 대한 다양한 효능이 밝혀지고 있음에도 불구하고, 현재 국내 고려인삼 및 홍삼제품은 인삼의 유효활성성분을 진세노사이드 Rg1, Rb1 및 Rg3에 관하여 단 3종만 개별인정과 규격화하고 있기 때문에 면역력증진, 피로회복, 혈소판 응집 억제를 통한 혈액흐름 개선, 기억력 개선, 항산화 작용 등 좁은 범위의 효능과 관련된 건강기능식품이 개발되고 있는 실정이다.As shown in [Table 2], Korean ginseng contains about 22 ginsenosides, and although various effects are scientifically revealed for about 22 ginsenosides, Korean ginseng and red ginseng are currently available in Korea. Since only 3 types of ginsenosides Rg 1 , Rb 1 and Rg 3 are recognized and standardized as active ingredients of ginseng, the product improves blood flow, improves memory, suppresses platelet aggregation, improves blood flow, improves memory, and antioxidants. Health functional foods related to a narrow range of efficacy, such as action is being developed.
고려인삼의 효능을 증강시키는 기술과 관련한 선행기술로 예를 들면, 국내 등록특허공보 등록번호 10-0439202호에 학습효능 강화 인삼식품을 개발하기 위하여 뇌기능 향상물질인 진세노사이드 Rg1의 함량이 높은 인삼농축액과 원지, 석창포, 산조인, 백복령, 오미자를 이용한 학습효능 강화 인삼식품 및 그 제조방법을 개시하고 있으며, 국내 공개특허공보 공개번호 10-2013-0027648호에는 홍삼농축액과 호도분말과 생약재 8종(용안육, 백복령, 진피, 원지, 석창포, 감초, 생강, 대추)의 혼합추출물과 레시틴과 물로 이루어진 기억력 증진용 조성물을 개시하고 있으며, 한국특허 공개번호 10-2011-0093477에는 항암효과가 탁월한 홍삼제품을 개발하기 위하여 홍삼액을 락토바실러스 플란타럼(Lactobacillus plantarum)으로 발효시켜 진세노사이드 F2, Rk3, Rh4 및 Rk1등 총사포닌 함량이 발효 전 홍삼액보다 1.4 배 이상 증가된, 항암효능이 있는 홍삼 발효액을 유효성분으로 함유하는 발효 홍삼을 포함하는 항암 조성물을 개시하고 있으며, 또 한국특허 공개번호 10-2009-0128625에는 체력, 면역증진과 스트레스 예방효능을 가진 클로렐라와 홍삼을 함유하는 홍삼 혼합 조성물을 개시하고 있으나 상기 선행기술들 역시 단순히 홍삼성분에 함유된 불특정의 진세노사이드의 효능을 이용하거나 홍삼성분 중 소수의 진세노사이드 성분의 효능을 이용하는 기술을 개시하고 있다.As a prior art related to the technology to enhance the efficacy of Korean ginseng, for example, in Korea Patent Publication No. 10-0439202 to develop a ginseng food for enhancing the efficacy of learning ginsenoside Rg1 high brain Ginseng concentrate, raw paper, Seokchangpo, Sanjoin, Baekbokryeong, and Schisandra chinensis to enhance the efficacy of learning ginseng food and its manufacturing method, Korean Patent Publication No. 10-2013-0027648 domestic red ginseng concentrate, Hodo powder and herbal medicine (Yongan meat, Baekbokyeong, dermis, raw paper, Seokchangpo, licorice, ginger, jujube) discloses a composition for enhancing memory consisting of lecithin and water, and Korean Patent Publication No. 10-2011-0093477 has excellent anti-cancer effect Ginsenoside F2, Rk3, Rh4 and Rk1 total saponins were fermented with Lactobacillus plantarum to develop Anti-cancer composition comprising fermented red ginseng containing red ginseng fermentation broth with anticancer activity as an active ingredient, the amount of which is increased 1.4 times or more than red ginseng liquor before fermentation, and also disclosed in Korean Patent Publication No. 10-2009-0128625 A red ginseng mixture composition containing chlorella and red ginseng having an anti-stress effect is disclosed, but the prior art also simply utilizes the effects of unspecified ginsenosides contained in the red ginseng component or uses a small number of ginsenoside components of the red ginseng component. Techniques for utilizing efficacy are disclosed.
본 발명은 과학적으로 그 효능이 밝혀진 홍삼에 함유된 다양한 종류의 진세노사이드 즉 11종의 진세노사이드에 대한 효능을 폭넓게 이용하면서 비타민 및 미네랄과 조합함으로써 현대사회에서 심각하게 대두되고 있는 항스트레스, 항고지혈증 및 항비만 활성화 효능을 가진 홍삼농축액 조성물과 이를 함유한 식품을 개발하게 되었다.The present invention is widely used in anti-stress of the modern society by combining with vitamins and minerals while widely utilizing the efficacy of various types of ginsenosides, that is, 11 types of ginsenosides contained in red ginseng, which have been scientifically proven. A red ginseng concentrate composition having anti-hyperlipidemic and anti-obesity activating effects and a food containing the same were developed.
본 발명은 홍삼농축액 분말, 비타민 및 미네랄로 조성된 항스트레스, 항고지혈증 및 항비만용 조성물 및 건강기능식품의 제공을 목적으로 하며, 구체적으로는 홍삼에 함유된 여러 진세노이드 성분들이 갖는 다양한 효능에 대하여 지속적인 연구를 수행함에 따라 11종의 진세노사이드를 정량적으로 포함하면서 비타민 및 미네랄로 조성하는 것에 의해 기존의 항스트레스 및 항고지혈증 및 항비만용 관련 제제들의 부작용을 최소화하면서 스트레스, 고지혈증 및 비만관련 질환의 예방 및 치료효과를 가질 수 있는 항스트레스, 항고지혈증 및 항비만용 조성물 및 건강기능식품을 제공하는 것을 목적으로 하는 것이다.The present invention aims to provide an anti-stress, anti-hyperlipidemic and anti-obesity composition and health functional food composed of red ginseng concentrate powder, vitamins and minerals, and specifically, various ginsenoid components contained in red ginseng. Consistent research on stress, hyperlipidemia and obesity, while quantitatively containing 11 ginsenosides and formulating them with vitamins and minerals, minimize side effects of existing antistress and antihyperlipidemic and antiobesity related agents An object of the present invention is to provide an antistress, antihyperlipidemic and anti-obesity composition and health functional food which can have a prophylactic and therapeutic effect.
본 발명은 기존의 항스트레스, 항고지혈증 및 항비만용 관련 제제들의 부작용을 해결하기 위한 항스트레스, 항고지혈증 및 항비만용 조성물로서, 11종의 진세노사이드를 유효성분으로 함유하는 홍삼농축액 분말과 비타민성분 및 미네랄성분을 일정비율로 조성하는 것으로 이루어진다. The present invention is an anti-stress, anti-hyperlipidemia and anti-obesity composition for solving the side effects of conventional anti-stress, anti-hyperlipidemia and anti-obesity related agents, red ginseng concentrate powder containing 11 ginsenosides as an active ingredient and It consists of forming a vitamin component and a mineral component in a certain ratio.
상기 홍삼농축액 분말에 유효성분으로 함유하는 11종의 진세노사이드는 Rg1, Re, Rf, Rb1, Rg2, Rc, Rb2, Rb3, Rd, Rg3 및 Rh2로 이루어지며, 또 상기 11종의 진세노사이드를 유효성분으로 함유하는 홍삼농축액 분말은 인삼산업법상의 규격으로 시판되고 있는 홍삼농축액을 원료로 하거나 또는 출원인{대동고려삼(주)}이 직접 인삼산업법상의 규격에 적합하도록 원료홍삼을 추출 및 농축한 원료 홍삼농축액을 1차적으로 경막결정화에 의해 상기 진세노사이드 11종에 대한 총사포닌 5중량%(50mg/g)이고, 고형분 65중량%의 홍삼농축액을 제조한 다음, 이를 분무건조하는 방식에 의해 홍삼농축액 분말을 제조하는 것으로 이루어진다.The 11 ginsenosides contained in the red ginseng concentrate powder as an active ingredient are composed of Rg 1 , Re, Rf, Rb 1 , Rg 2 , Rc, Rb 2 , Rb 3 , Rd, Rg 3 and Rh 2 , and The red ginseng concentrate powder containing 11 kinds of ginsenosides as an active ingredient is made from red ginseng concentrate commercially available as the standard under the Ginseng Industry Act or the applicant {Daedong Korea Ginseng Co., Ltd.} directly meets the standard under the Ginseng Industry Act. Raw red ginseng concentrate extracted and concentrated to make red ginseng concentrate of 5% by weight (50mg / g) and 65% by weight of solid saponin to 11 ginsenosides was first prepared by transmembrane crystallization. It consists of preparing the red ginseng concentrate powder by spray drying.
상기 본 발명에 따른 홍삼농축액 분말은 상기 홍삼농축액 원료에 순도 95중량%의 주정을 혼합하고, 경막결정화기로 투입한 다음, -20℃ 온도에서 1시간동안 일정하게 유지하면서 결정화를 유도하여 1차 홍상농축액을 제조한 다음 1차 홍삼농축액을 In let Temp. 180 ~ 190℃ 및 Out let Temp. 80~85℃ 조건의 노즐분무식 분무건조장치로 분무 건조하여 홍삼농축액 분말을 제조하는 것으로 이루어진다.The red ginseng concentrate powder according to the present invention is a red ginseng concentrate raw material with a purity of 95% by weight mixed with a raw material, put into a film crystallization, and then maintained at a constant temperature for 1 hour at -20 ℃ temperature to induce crystallization Hong Sang concentrate was prepared, and the first red ginseng concentrate was added to In let Temp. 180 ~ 190 ° C and Out let Temp. Spray drying with a nozzle spray spray drying apparatus at 80 ~ 85 ℃ condition consists of preparing a red ginseng concentrate powder.
본 발명은 상기 원료 홍삼농축액으로부터 경막결정화 및 분무건조의 공정을 이용함으로써 상기 홍삼농축액 원료로부터 상기 11종의 진세노사이드의 총 함량이 홍삼농축액 분말 중에 5.5 내지 7.5중량% 함유하는 홍삼농축액 분말을 제조할 수 있으며, 이러한 기술에 의해 상기 11종의 진세노사이드의 총 함량이 6.5중량% 함유하도록 정량 표준화하는 것이 가능하다. The present invention prepares red ginseng concentrate powder containing 5.5 to 7.5 wt% of the total content of the 11 ginsenosides in the red ginseng concentrate powder from the red ginseng concentrate raw material by using a process of dural crystallization and spray drying from the raw red ginseng concentrate. By this technique, it is possible to standardize quantitatively so that the total content of the 11 ginsenosides is 6.5% by weight.
상기 본 발명에 따른 홍삼농축액 분말은 본 발명에 따른 항스트레스, 항고지혈증 및 항비만용 조성물 총중량에 대하여 20 ~ 35중량%로 조성되며 또 상기 11종의 진세노사이드의 총 함량은 홍삼농축액 분말 중에 5.5 내지 7.5중량% 함유하며, 상기 11종의 진세노사이드 함유량은 홍삼농축액 분말 단위중량(g)당 Rg1 7.5 ~ 8.5㎎, Re 10 ~ 11.5㎎, Rf 1.8 ~ 2.5㎎, Rb1 20 ~ 23㎎, Rg2 0.8 ~ 1㎎, Rc 6 ~ 8㎎, Rb2 8 ~ 9.5㎎, Rb3 1.8 ~ 2.2㎎, Rd 3.5 ~ 4.5㎎, Rg3 0.5㎎, Rh2 0.01㎎을 함유하는 것으로 이루어진다.The red ginseng concentrate powder according to the present invention is composed of 20 to 35% by weight relative to the total weight of the anti-stress, antihyperlipidemia and anti-obesity composition according to the present invention and the total content of the 11 ginsenosides in the red ginseng concentrate powder 5.5 to 7.5% by weight, and the ginsenoside content of the 11 species is Rg 1 7.5 ~ 8.5mg,
상기 본 발명에 조성되는 비타민성분으로는 비타민B1, B2, 비타민C, 나이아신, 판토텐산, 비오틴 및 엽산을 조성하는 것으로 이루어지며, 비타민성분별 조합비율은 본 발명의 항스트레스, 항고지열증 및 항비만용 조성물 총 충량에 대하여 비타민B1 5 ~10중량%, B2 2중량%, 비타민C 25중량%, 나이아신 2중량%, 판토텐산 22 ~ 27중량% 비오틴 0.04중량% 및 엽산 0.01중량%로 조성되며, 비타민 성분의 총함량은 상기 조성물 총중량에 대하여 56.05 ~ 66.05중량%로 함유되는 것으로 이루어진다.The vitamin component of the present invention is composed of vitamin B 1 , B 2 , vitamin C, niacin, pantothenic acid, biotin and folic acid, the combination ratio of each vitamin component is antistress, antihyperlipidemia and Vitamin B 1 5 to 10% by weight,
또 본 발명에 따른 미네랄성분은 마그네슘, 셀레늄, 요오드 철 및 망간의 공급원으로 스테아린산 마그네슘, 셀레늄, 환원철, 요오드화칼륨 및 황산망간을 조성하는 것으로 이루어지며, 미네랄성분별 조합비율은 상기 본 발명에 따른 조성물 총 중량에 대하여 스테아린산 마그네슘 1 ~ 10.5중량%, 셀레늄 1 ~ 2.5중량%, 환원철 0.3 ~ 0.5중량%, 요오드화 칼륨 0.005 ~ 0.01중량%, 황산망간 0.3 ~ 0.5중량% 로 조성되며 미네랄 성분의 총함량은 조성물 총중량에 대하여 2.605 ~ 14.01중량%이하로 함유되는 것으로 이루어진다. In addition, the mineral component according to the present invention is composed of magnesium stearate, selenium, reduced iron, potassium iodide and manganese sulfate as a source of magnesium, selenium, iron iodine and manganese, the composition ratio of each mineral component according to the
상기 본 발명에 따른 항스트레스, 항고지혈증 및 항비만용 조성물은 통상의 방법에 따라 적절한 담체, 부형제 및 희석제와 추가로 조합될 수 있으며 담체, 부형제 및 희석제로는 락토오즈, 텍스트로오즈, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말니톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘실리케이트, 셀룰로오즈, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물류를 예로 들 수 있다.The composition for antistress, antihyperlipidemia and anti-obesity according to the present invention may be further combined with a suitable carrier, excipient and diluent according to a conventional method, and the carrier, excipient and diluent may be lactose, textose, sucrose, Sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water methylhydroxy benzoate, propylhydride Roxy benzoate, talc, magnesium stearate and minerals are exemplified.
또한 본 발명의 항스트레스, 항고지혈증 및 항비만용 조성물은 통상의 방법에 따라 산제, 과립제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형의 형태로 제형화되어 건강 보조식품 및 음료 등으로 다양하게 적용될 수 있다.In addition, the anti-stress, anti-hyperlipidemic and anti-obesity compositions of the present invention are formulated in the form of oral dosage forms, such as powders, granules, capsules, suspensions, emulsions, syrups, etc. It can be applied in various ways.
그리고 본 발명의 항스트레스, 항고지혈증 및 항비만용 조성물의 사용량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 0.1% 내지 100 mg/kg의 양을 하루 1회 내지 수회 경구투여할 수 있다.And the amount of the anti-stress, anti-hyperlipidemia and anti-obesity composition of the present invention may vary depending on the age, sex, and weight of the patient, but the amount of 0.1% to 100 mg / kg may be administered orally once or several times a day. .
본 발명은 인삼의 유효활성성분인 진세노사이드 Rg1, Rb1 및 Rg3에 한정되지 않고 11종의 진세노사이드의 효능을 이용한 항스트레스, 항고지혈증 및 항비만용 조성물을 건강식품으로 제공되어 부작용을 최소화하면서 스트레스, 고지혈증 및 비만관련 질환의 예방 및 치료효과를 나타내는 특징이 있다.The present invention is not limited to ginsenosides Rg 1 , Rb 1 and Rg 3 of the active ingredients of ginseng, antistress, antihyperlipidemia and anti-obesity compositions using the efficacy of 11 kinds of ginsenosides are provided as a health food Minimize side effects and have the characteristics of preventing and treating stress, hyperlipidemia and obesity-related diseases.
특히, 본 발명은 인삼의 유효활성성분인 진세노사이드 Rg1, Rb1 및 Rg3에 한정되지 않고 홍삼에 함유된 11종의 진세노사이드의 다양한 성분을 항스트레스, 항고지혈증 및 항비만용 조성물로 제공함으로써 홍삼의 유효가치를 더욱 개선하여 홍삼제품의 상품가치를 향상시키는 특징이 있다.In particular, the present invention is not limited to ginsenosides Rg 1 , Rb 1 and Rg 3 , which are the active ingredients of ginseng, and various components of the 11 kinds of ginsenosides contained in red ginseng for antistress, antihyperlipidemia and anti-obesity composition. By improving the effective value of red ginseng by further improving the product value of red ginseng products.
[도 1]은 본 발명의 홍삼농축액 및 홍삼농축액분말의 HPLC 데이터.
[도 2]은 본 발명의 시료 SN6 및 SN11와 Pharmaton(대조)을 투여한 마우스의 강제수영부하 부동시간을 나타내는 도면.
[도 3]는 본 발명의 시료 SN6 및 SN11, Pharmaton(비교)을 투여한 마우스의 트레드밀 운동지속시간을 나타내는 도면.
[도 4]은 본 발명의 시료 SN6, SN11 및 Pharmaton(비교) 투여에 의한 각 장기 중량의 변화를 나타내는 도면.
[도 5]는 본 발명의 시료 SN6, SN11 및 Pharmaton(비교) 경구투여에 의한 간독성 을 측정한 도면.
[도 6]는 본 발명의 시료 SN6, SN11 및 Pharmaton(비교) 경구투여에 의한 신독성 을 측정한 도면.
[도 7]은 HFD 급이 마우스에서 본 발명의 시료 SN6, SN11와 Pharmaton(비교) Fenofibrate(비교)의 항비만 효과를 나타내는 도면.
[도 8]은 FD 급이 마우스에서 본 발명의 시료 SN6, SN11와 Pharmaton(비교) Fenofibrate(비교)의 복부지방 억제 효과를 나타내는 도면.
[도 9]은 HFD 급이 마우스에서 본 발명의 시료 SN6, SN11의 혈중지방 LDL 억제효과를 나타내는 도면.1 is HPLC data of red ginseng concentrate and red ginseng concentrate powder of the present invention.
2 is a diagram showing the forced swimming load dead time of mice administered the samples SN6 and SN11 and Pharmaton (control) of the present invention.
3 is a diagram showing the treadmill movement duration of mice administered the samples SN6 and SN11, Pharmaton (comparative) of the present invention.
4 is a view showing the change in the weight of each organ by administration of samples SN6, SN11 and Pharmaton (comparative) of the present invention.
Figure 5 is a measure of hepatotoxicity by oral administration of samples SN6, SN11 and Pharmaton (comparative) of the present invention.
Figure 6 is a measure of the renal toxicity by oral administration of samples SN6, SN11 and Pharmaton (comparative) of the present invention.
7 is a diagram showing the anti-obesity effect of the samples SN6, SN11 and Pharmaton (comparative) Fenofibrate (comparative) of the present invention in HFD fed mice.
8 is a diagram showing the abdominal fat inhibitory effect of the samples SN6, SN11 and Pharmaton (comparative) Fenofibrate (comparative) of the present invention in FD fed mice.
9 is a diagram showing the blood fat LDL inhibitory effect of samples SN6 and SN11 of the present invention in HFD- fed mice.
이하에서는 실시예 및 시험예를 통하여 본 발명을 더욱 구체적으로 설명하겠으며, 아래 실시예 및 시험예의 기재에 의해 본 발명이 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples, and the present invention is not limited by the following Examples and Test Examples.
또, 본 발명에서 사용하는 부 및 퍼센트의 단위는 특별한 기재가 없는 한 모두 중량으로 나타낸 것이다.In addition, the part and the unit of a percentage used by this invention are shown by weight unless there is particular notice.
그리고 본 발명의 실시예에서 진세노사이드 11종의 함량에 대한 계산식은 아래 나타낸 [표 3]에 따라 계산한 것이며, 진세노사이드 11종의 함량분석은 식품공전의 전처리 방법에 따라 각각 분석샘플을 제조한 후, UVD(Ultra Visible Detector)가 장착된 HPLC(High Performance Liquid Chromatography)로 아래 나타낸 [표 4]와 같다.And the formula for the content of the ginsenoside 11 species in the embodiment of the present invention was calculated according to [Table 3] shown below, the content analysis of the 11 ginsenosides according to the pretreatment method of the food industry, respectively, the analysis sample After the preparation, it is shown in [Table 4] shown below by HPLC (High Performance Liquid Chromatography) equipped with UVD (Ultra Visible Detector).
진세노사이드 함량(mg/g) :
Ginsenoside content (mg / g):
S: 시험용액 중 개별 진세노사이드 함량 (㎎/g)
a: 시험용액의 전량(㎖)
b: 희석배수
S: Individual Ginsenosides Content in Test Solution (mg / g)
a: total amount of test solution (ml)
b: dilution factor
(4.6mm× 250mm, 5.0㎛)Frontosil 120-5-C18-ace-EPS
(4.6mm × 250mm, 5.0㎛)
- Mobile phase
-Mobile phase
<실시예 1>≪ Example 1 >
a). 홍삼농축액 제조a). Manufacture of red ginseng concentrate
대동고려삼(주)(본 발명의 출원인)에서 원료홍삼(국내산 6년근)을 이용하여 추출 및 농축하여 아래 [표 5]와 같이 11종의 진세노사이드 함량이 38.894mg/g이고, 고형분 함량이 60wt%의 홍삼농축액(시판제품)을 원료로 사용하였다. Extracted and concentrated using raw red ginseng (6 years old domestic) in Daedong Korea ginseng Co., Ltd. (applicant of the present invention), the ginsenoside content of the 11 species is 38.894mg / g, as shown in Table 5 below, the solid content Red ginseng concentrate (commercially available product) of 60wt% was used as a raw material.
상기 원료 홍삼농축액 10㎏에 대하여 순도 95중량% 주정을 10중량%로 혼합하여 준비한 후, 내경 8cm, 외경 9.5cm, 높이 40cm로 구성된 이중쟈켓형의 유리재질로 구성되어있고, 이중쟈켓관을 통하여 일정한 유속의 냉매가 결정화 온도를 제어할 수 있게 되어있는 경막결정화기에 투입하고, 경막결정화기의 온도를 -20℃로 경막결정화기의 벽면으로 결정화를 유도하면서 1시간동안 일정하게 유지한 다음, 액상물을 분리시키고 경막결정화기의 벽면에 석출된 결정을 수득하여 상온으로 유지하면서 결정물을 액상으로 하여 진세노사이드 11종에 대한 총사포닌 5wt%(50mg/g) 및 고형분 65wt%의 홍삼농축액 8kg을 수득하였으며, 11종에 대한 총사포닌의 HPLC데이터 및 분석 결과를 아래 [표 6] 및 [도1]로 나타내었다.The raw material of red ginseng concentrate was prepared by mixing 10 wt% of 95 wt% spirit alcohol with 10 kg of purity, and then composed of a double jacket type glass material composed of an inner diameter of 8 cm, an outer diameter of 9.5 cm, and a height of 40 cm. Refrigerant of a constant flow rate is put into a film crystallization device which can control the crystallization temperature, and the film is kept constant for 1 hour while inducing crystallization to the wall surface of the film crystallizer at -20 ° C. Isolates the liquid and obtains the crystals deposited on the wall of the dura-crystallizer. The crystals are kept in the liquid state while maintaining the room temperature. The red ginseng concentrate of 5 wt% (50 mg / g) and 65 wt% of the solid content of ginsenosides is obtained. 8 kg were obtained, and HPLC data and analysis of total saponin of 11 species are shown in Table 6 and FIG. 1 below.
상기 수득한 진세노사이드 11종에 대한 총사포닌은 5% (50mg/g) 및 고형분은 65%로 홍삼농축액을 정제수로 고형분 25%로 희석하여 In let Temp. 180℃ 및 Out let Temp. 85℃의 조건의 노즐분무식 분무건조장치로 분무 건조하여 홍삼농축액분말을 제조하였으며, 이를 3회에 걸쳐 수행하고, 11종의 진세노이드 함량 6.5% 이상 함유되는 홍삼농축액분말 수득할 수 있었으며, 홍삼농축액 분말의 11종에 대한 총사포닌의 HPLC데이터 및 분석 결과를 아래 [표 6] 및 [도 1]로 나타내었다.The total saponins of the eleven ginsenosides obtained were 5% (50 mg / g) and 65% solids, and red ginseng concentrate was diluted with purified water to 25% solids. 180 ° C. and Out let Temp. The red ginseng concentrate powder was prepared by spray drying with a nozzle spray spray drying apparatus at 85 ° C., which was carried out three times, and the red ginseng concentrate powder containing 6.5% or more of 11 ginsenosides was obtained. HPLC data and analysis results of total saponins of 11 kinds of concentrate powders are shown in the following [Table 6] and [FIG. 1].
상기 [표 6]에 나타난 바와 같이 5% 정량 홍삼농축액의 진세노사이드 11종에 대한 HPLC분석결과 개별 진세노사이드는 Rb1 6.20mg/g, Re 8.30mg/g, Rf 1.57mg/g, Rb1 16.40mg/g, Rg2 0.70mg/g, Rc 5.00mg/g, Rb2 6.80mg/g, Rb3 1.62mg/g, Rd 3.00mg/g, Rg3 0.40mg/g 및 Rh2 0.01mg/g 등으로 각각 분석되었고, 진세노사이드 11종에 대한 총사포닌은 5% (50mg/g) 및 고형분은 65%로 나타내는 것을 확인할 수 있으므로 본 발명의 농축공정에 의한 홍삼농축액은 5% 정량 홍삼농축액으로 제조할 수 있음을 알 수 있었다.As shown in [Table 6], HPLC analysis of 11 ginsenosides of 5% quantitative red ginseng concentrate showed Rb 1 6.20 mg / g, Re 8.30 mg / g, Rf 1.57 mg / g, and Rb. 1 16.40 mg / g, Rg 2 0.70 mg / g, Rc 5.00 mg / g, Rb 2 6.80 mg / g, Rb 3 1.62 mg / g, Rd 3.00 mg / g, Rg 3 0.40 mg / g and Rh 2 0.01 mg / g and the like, respectively, and ginsenosides for the total 11 ginseng, 5% (50mg / g) and solids can be seen that represent 65%, so the red ginseng concentrate by the concentration process of the present invention 5% quantitative red ginseng It can be seen that it can be prepared as a concentrate.
또 상기 [표 6]에 나타난 바와 같이 5% 정량 홍삼농축액을 이용하여 상기의 노즐 분사식 분무건조에서 총 3회 동일한 실험을 진행하여 얻어진 홍삼농축액분말들의 진세노사이드 11종에 대한 HPLC분석결과에 의해 Rb1 8.05mg/g, Re 10.80mg/g, Rf 2.04mg/g, Rb1 21.35mg/g, Rg2 0.90mg/g, Rc 6.50mg/g, Rb2 8.85mg/g, Rb3 2.10mg/g, Rd 3.90mg/g, Rg3 0.50mg/g 및 Rh2 0.01mg/g 으로 진세노사이드 11종에 대해 각각 정량화된 분말을 얻을 수 있었으며, 진세노사이드 11종에 대한 총진세노사이드는 6.5% (65mg/g)± 1%로 정량화된 홍삼농축액 분말을 제조할 수 있었다.In addition, as shown in [Table 6] by using the 5% quantitative red ginseng concentrate by the HPLC analysis results for 11 ginsenosides of the red ginseng concentrate powder obtained by performing the same experiment three times in the nozzle spray spray drying Rb 1 8.05mg / g, Re 10.80mg / g, Rf 2.04mg / g, Rb 1 21.35mg / g, Rg 2 0.90mg / g, Rc 6.50mg / g, Rb 2 8.85mg / g, Rb 3 2.10mg / g, Rd 3.90mg / g, Rg 3 0.50mg / g and Rh 2 0.01mg / g to obtain powders quantified for each of 11 ginsenosides, the total ginsenosides for 11 ginsenosides Red ginseng concentrate powder quantified at 6.5% (65 mg / g) ± 1% could be prepared.
<실시예 2><Example 2>
- 정량 홍삼농축액분말 , 비타민류 및 미네랄류 혼합제제의 제조 - Determination Preparation of Red Ginseng extract powder, vitamins and minerals mixed formulation
상기 실시예 1에서 제조한 5%정량 홍삼농축액로부터 얻은 홍삼농축액분말, 비타민류 및 미네랄류를 아래 [표 7]과 같이 혼합한 시료 SN6 및 SN11를 제조하였다.Samples SN6 and SN11 were prepared by mixing red ginseng concentrate powder, vitamins and minerals obtained from the 5% quantitative red ginseng concentrate prepared in Example 1 as shown in Table 7 below.
<실험예><Experimental Example>
A 강제수영부하 실험, 트레드밀을 이용한 실험 및 독성실험A Forced Swimming Load Test, Treadmill Test and Toxicity Test
상기 실시예 2에서 제조한 정SN6, SN11와 비교를 위하여 항스트레스 및 신체에너지 활성용 파마톤사의 영양제인 파마톤정(Pharmaton)을 사용하여 항스트레스, 신체활성 실험을 아래와 같은 조건에서 진행하였다. In order to compare the tablets SN6 and SN11 prepared in Example 2, anti-stress and physical activity experiments were conducted under the following conditions using Pharmaton (Pharmaton), a nutritional agent of Pharmaton for antistress and physical energy activity.
아래 강제수영부하, 트레드밀 실험 및 독성실험에 사용된 동물은 7주령 암컷 Balb/c 마우스를 실험군별로 10마리씩 사용하여 수차례 반복 실험하였으며, 실험에 사용한 마우스는 (주)대한동물센터로부터 입수하였고, 전반적인 실험 동물 관리는 국제적인 US guidelines (NIH publication #85-23, revised in 1985) 실험기준에 따라 준비하였다.The animals used in the following forced swimming load, treadmill test and toxicity test were repeated several times using 10 7-week-old female Balb / c mice for each experimental group, and the mice used for the experiment were obtained from the Korea Animal Center. Overall experimental animal care was prepared according to international US guidelines (NIH publication # 85-23, revised in 1985).
시험을 위하여 SN6 및 SN11과 파마톤정제의 마우스에 대한 급이는 1일 1회 총 5일간 3mg/mouse씩 각각 경구투여하였다.For the test, the mice fed SN6, SN11 and Pharmaton tablets were orally administered 3 mg / mouse once a day for a total of 5 days.
독성실험을 위한 혈청학적 검사에서는 DryChem 3500i (Fuji Lab., Japan) 혈액분석장치를 이용하여 간독성(GOT 및 GPT)과 신독성(CRE 및 BUN)을 조사하였다 {GOT:Glutamic Oxaloacetic Transaminase, GPT: Glutamic Pyruvic Transaminase, CRE: Creatinine, BUN: Blood Urea Nitrogen}.In serological tests for toxicity studies, hepatotoxicity (GOT and GPT) and nephrotoxicity (CRE and BUN) were examined using a DryChem 3500i (Fuji Lab., Japan) blood analyzer. {GOT: Glutamic Oxaloacetic Transaminase, GPT: Glutamic Pyruvic Transaminase, CRE: Creatinine, BUN: Blood Urea Nitrogen}.
1) 강제수영부하 실험 1) Forced swimming load test
강제수영부하 실험은 Porsolt 방법에 의해 진행되었다. 미리 제조된 사각 cage(높이: 25cm, 가로×세로:12× 22cm)에 물을 채운 후, 두 개의 플라스틱 실린더 (높이: 25cm, 반경: 10cm)를 세워 높고, 온도는 25℃로 유지하여 실행되었다. 두 개의 플라스틱 실린더 각각에 실험동물을 넣고 2분간 수영을 시켜 익숙시킨 후에 4분동안 수영을 시키면서 동작이 멈추는 시간(Immobility time, sec)을 측정하여 강제수영부하 시험의 부동시간을 측정하였으며 시험결과를 [도 2]에 나타내었다Forced swimming experiment was performed by Porsolt method. After filling water into a prefabricated square cage (height: 25 cm, width x length: 12 x 22 cm), two plastic cylinders (height: 25 cm, radius: 10 cm) were raised and held at a high temperature of 25 ° C. . The experimental animals were placed in each of the two plastic cylinders for 2 minutes, and then used to swim for 4 minutes. After the swimming was stopped for 4 minutes, the immobilization time (sec) was measured. 2 is shown.
[도 2]을 참조하면, SN6와 SN11, Pharmaton(파마톤정)을 투여한 마우스의 항스트레스 및 신체에너지 활성을 측정하기 위하여, 5일간 각 시료를 경구투여한 마우스와 시료를 투여하지 않은 Control(대조군 마우스) 마우스의 강제수영부하에 대한 부동시간을 측정하였다. 그 결과 SN6은 Pharmaton(파마톤정)과 동등한 수준의 부동시간을 나타내었으며, SN11은 Pharmaton(파마톤정) 보다도 높은 저항성을 지니는 것으로 확인되었고, 전체적으로는 시료를 투여하지 않은 Control 마우스에 비하여 SN6와 SN11 시료를 투여한 마우스의 부동시간이 확연히 감소됨을 알 수 있었다.2, in order to measure the antistress and body energy activity of mice administered SN6, SN11, and Pharmaton (Pharmaton tablets), mice orally administered each sample for 5 days and Control (not administered) ( Control mice) The immobility time for the forced swimming load of the mice was measured. As a result, SN6 showed the same immobility time as Pharmaton (Pharmaton tablets), and SN11 had higher resistance than Pharmaton (Pharmaton tablets). Overall, SN6 and SN11 samples were compared to control mice that did not receive the samples. It can be seen that the immobility time of the mice to which administration was significantly reduced.
2) 트레드밀 실험2) Treadmill Experiment
트레드밀을 이용한 실험은 (주)정도비엔피의 트레드밀 JD-A-09 모델을 사용하여 진행되었다. 트레드밀의 주행속도는 20m/min, 경사각도는 5°의 조건에서 마우스를 1분간 트레드밀에 적응할 수 있도록 연습시킨 후에, 1분동안에 트레드밀에서 떨어지지 않고 견뎌내는 시간(endurance time)을 측정하여 판정하였다([도 3] 참조)The experiment using the treadmill was carried out using the treadmill JD-A-09 model of Jeongdo Bienp Co., Ltd. The treadmill was run at a speed of 20 m / min and an inclination angle of 5 ° to allow the mouse to adapt to the treadmill for 1 minute, and then measured by measuring endurance time without falling off the treadmill for 1 minute ( (See Fig. 3)
[도 3]를 참조하면, SN6와 SN11, Pharmaton(파마톤정)을 투여한 마우스의 항스트레스 및 신체에너지 활성을 측정하기 위하여, 5일간 각 시료를 경구투여한 마우스와 시료를 투여하지 않은 Control(대조군 마우스) 마우스의 트레드밀에 대한 운동지속시간을 측정하였다. 그 결과 SN6은 Pharmaton(파마톤정)보다 높은 수준의 운동지속시간을 나타내었으며, SN11은 Pharmaton(파마톤정) 보다도 낮은 수준의 운동지속시간을 나타내었고, 전체적으로는 시료를 투여하지 않은 Control 마우스에 비하여 SN6와 SN11 시료를 투여한 마우스의 운동지속시간이 확연히 증가됨을 알 수 있었다.Referring to FIG. 3, in order to measure antistress and physical energy activity of mice administered SN6, SN11, and Pharmaton (Pharmaton tablets), mice orally administered each sample for 5 days and Control (not administered) ( Control mice) The exercise duration for the treadmill of the mouse was measured. As a result, SN6 showed a higher level of exercise duration than Pharmaton (Pharmaton tablets), and SN11 showed a lower level of exercise duration than Pharmaton (Pharmaton tablets). It was found that the exercise duration of mice treated with and SN11 samples increased significantly.
3) 독성실험3) Toxicity Test
독성실험은 1일 1회씩 5일간 SN6, SN11 및 Pharmaton을 3 mg/mouse의 양으로 경구 투여한 경우, 마우스에 대해 독성을 나타내는 가를 검토하기 위하여, 시료를 경구 투여하기 시작한 2일, 4일, 6일째의 마우스의 체중변화와 간독성 및 신독성 발현 여부를 조사하였다. Toxicity experiments were performed 2 or 4 days after the oral administration of the samples to examine whether the mice were toxic for oral administration of SN6, SN11 and Pharmaton at a dose of 3 mg / mouse once daily for 5 days. We examined the weight change and hepatotoxicity and nephrotoxicity of mice on day 6.
간독성은 GOT와 GPT를, 신독성은 CRE와 BUN의 혈중농도를 측정하여 [도 4], [도 5] 및 [그림 6]에 나타내었다.Hepatotoxicity was shown in GOT and GPT, and renal toxicity was measured in blood concentrations of CRE and BUN in [Figure 4], [Figure 5] and [Figure 6].
[도 4]을 참조하면, 대조군의 마우스와 비교하였을 때, SN6와 SN11 및 Pharmaton의 경구 투여처리하였을 경우에도 간, 비장, 폐, 신장의 중량에 있어서도 아무런 변화가 관찰되지 않았다.Referring to FIG. 4, no changes were observed in liver, spleen, lung, and kidney weights even when orally administered SN6, SN11, and Pharmaton when compared to mice in the control group.
[그림 5] 와 [그림 6]를 참조하면, 간독성(GOT 및 GPT)과 신독성(CRE 및 BUN)을 측정한 결과에서도 대조군에 비하여 본 발명에 따른 조성물의 경구투여 처리에서도 특별한 독성은 관찰되지 않았다. 이들 결과로부터 SN6와 SN11는 3 mg/mouse의 양으로 5회 경구투여할 경우, 독성은 나타나지 않으며 강제수영부하에 대한 저항성과 운동능력의 증가를 유도하는 항스트레스 활성이 있는 것으로 판단되었다. Referring to [Fig. 5] and [Fig. 6], even when the liver toxicity (GOT and GPT) and the renal toxicity (CRE and BUN) were measured, no special toxicity was observed in the oral administration of the composition according to the present invention compared to the control. Did. These results indicate that SN6 and SN11 do not show toxicity when administered orally at 3 mg / mouse for five times, and have antistress activity which induces resistance to forced swimming and increases exercise capacity.
<실험예 2><Experimental Example 2>
항비만Anti-obesity 및 고지혈증 효과 실험 And hyperlipidemic effect experiment
항비만 및 고지혈증 효과 실험에서, 사용된 동물은 7주령 수컷 ICR 마우스를 실험군별로 10마리씩 사용하여 수차례 반복 실험하였다. 하기 실험에 사용한 마우스는 (주)대한동물센터로부터 입수하였고, 전반적인 실험 동물 관리는 국제적인 US guidelines (NIH publication #85-23, revised in 1985) 실험기준에 따라 준비하였다In the anti-obesity and hyperlipidemic effect experiments, the animals used were repeated several times using 10 7-week-old male ICR mice in each experimental group. Mice used for the following experiments were obtained from the Korea Animal Center Co., Ltd., and overall experimental animal care was prepared according to international US guidelines (NIH publication # 85-23, revised in 1985).
실험방법으로는 실험대조군으로 4주간 무처리 급이의 마우스, 대사성 질환의 하나인 비만과 고지혈증을 유발하기 위하여 60.3%(kcal)의 고지방 사료(High-fat diet: HFD)만 4주간 1일 1회 3mg/mouse씩 경구 투여한 마우스, 상기와 동일하게 HFD를 처리하면서 본 특허에서 제조된 SN6, SN11 및 파마톤정제를 1일 1회 총 4주간 3mg/mouse씩 각각 경구투여한 마우스 및 양성대조군으로 항고지혈증 및 항비만용 치료제로 사용되고 있는 fenofibrate를 4주간 1일 1회 2mg/mouse씩 경구투여한 마우스 등을 대상으로 1주 간격으로 체중에 대한 분석을 진행하였다. 단 복부지방검사 및 고지혈증용 혈액검사는 4주 째의 각각 시험대상 마우스에 대하여 분석하였다.As an experimental control group, 4 weeks of untreated rats, metabolic diseases, obesity and hyperlipidemia, 60.3% (kcal) high-fat diet (HFD) alone for 4 weeks, 1 week for 4 weeks. Mice administered orally 3 mg / mouse twice, mice treated with HFD in the same manner as above, and treated with 6 mg / mouse of SN6, SN11 and Pharmaton tablets prepared in this patent once a day for a total of 4 weeks, respectively. We analyzed the body weights at weekly intervals in mice administered orally with fenofibrate, which is used as an anti-hyperlipidemic and anti-obesity agent, 2mg / mouse once a day for 4 weeks. However, abdominal fat test and hyperlipidemia blood test were analyzed for each of the test mice at 4 weeks.
1) 항비만 효과 실험결과1) Anti-obesity effect test result
항비만 효과 실험결과는 [도 7]과 [도 8]에 나타내었으며, [그림 7]을 참조하면, 대조군(Control)마우스에 비하여 HFD를 경구투여한 마우스는 지속적으로 몸무게가 증가하는 것을 알 수 있고, SN6와 SN11은 모두 경구투여 개시 2주 후부터 현저한 체중증가 억제활성을 나타내었다. 특히 SN6는 양성 대조군인 fenofibrate와 거의 유사한 항비만 활성을 보였으며, SN11은 비교군인 파마톤보다도 높은 비만 억제활성을 지니는 것으로 관찰되었다.The results of the anti-obesity effect experiment are shown in [Fig. 7] and [Fig. 8]. Referring to [Fig. 7], it can be seen that the mice which received oral HFD continuously gained weight compared to the control mice. Both SN6 and SN11 showed significant weight gain inhibitory activity two weeks after the start of oral administration. In particular, SN6 showed almost similar anti-obesity activity as fenofibrate, a positive control, and SN11 had higher anti-obesity activity than the comparison group Pharmaton.
한편, [도 8]을 참조하면, HFD 경구 투여 개시 30일째의 마우스를 이용하여 복부지방 축적양을 비교하였다. 그 결과 SN6와 SN11은 양성대조군인 fenofibrate 및 비교군인 파마톤과 비교하여 동등 혹은 보다 더 높은 수준의 복부지방 축적 억제효과를 나타내는 것으로 확인되었다. Meanwhile, referring to FIG. 8, abdominal fat accumulation amount was compared using mice at 30 days from the start of HFD oral administration. As a result, SN6 and SN11 showed the same or higher level of abdominal fat accumulation inhibitory effect compared to fenofibrate, a positive control group, and Pharmaton, a control group.
2) 고지혈증 효과 실험결과2) Hyperlipidemic effect test result
고지혈증 효과 실험결과는 혈중 지질성분 축적 유발인자인 Low-Density Lipoprotein(LDL)의 혈중농도를 측정하여 [도 9]에 나타내었으며, [도 9]을 참조하면, Normal상태의 마우스에 비해 HFD 경구투여 마우스의 LDL수치는 급격히 증가한 것을 알 수 있고, HFD처리 마우스에 비하여 Finofibrate, Phamaton 및 SN6 등의 경우 LDL 감소효과가 유사한 수준에서 감소되어 나타났고, SN11 경구투입군에서는 현저하게 감소하였다.Hyperlipidemic effect test results are shown in [Fig. 9] by measuring the blood concentration of low-density lipoprotein (LDL), a lipid-induced accumulation factor factor in blood, referring to [Fig. 9], HFD oral administration compared to normal mice The LDL levels of the mice were rapidly increased, and the LDL-reducing effects of Finofibrate, Phamaton, and SN6 were decreased at similar levels compared to HFD-treated mice, and significantly decreased in the SN11 oral group.
Claims (4)
a) 상기 11종의 진세노사이드는 상기 홍삼농축액 분말 단위중량(g)당 Rg1 7.5 ~ 8.5㎎, Re 10 ~ 11.5㎎, Rf 1.8 ~ 2.5㎎, Rb1 20 ~ 23㎎, Rg2 0.8 ~ 1㎎, Rc 6 ~ 8㎎, Rb2 8 ~ 9.5㎎, Rb3 1.8 ~ 2.2㎎, Rd 3.5 ~ 4.5㎎, Rg3 0.5㎎, Rh2 0.01㎎ 함유하고,
b) 상기 비타민성분은 조성물 총 충량에 대하여 비타민B1 5 ~10중량%, B2 2중량%, 비타민C 25중량%, 나이아신 2중량%, 판토텐산 22 ~ 27중량% 비오틴 0.04중량% 및 엽산 0.01중량%로 조성되며,
c)상기 미네랄성분은 조성물 총 중량에 대하여 스테아린산 마그네슘 1 ~ 10.5중량%, 셀레늄 1 ~ 2.5중량%, 환원철 0.3 ~ 0.5중량%, 요오드화 칼륨 0.005 ~ 0.01중량%, 황산망간 0.3 ~ 0.5중량% 로 조성되는 것을 특징으로 하는 항스트레스, 항고지혈증 및 항비만용 조성물.Red ginseng concentrate powder containing 11 kinds of ginsenosides as an active ingredient, 20 to 35% by weight of vitamin components 56.05 to 66.05% by weight and mineral components 2.605 to 14.01% by weight,
a) The ginsenosides of the 11 species is Rg 1 per unit weight (g) of the red ginseng concentrate powder 7.5 to 8.5 mg, Re 10 to 11.5 mg, Rf 1.8 to 2.5 mg, Rb 1 20 to 23 mg, Rg 2 0.8 to 1 mg, Rc 6 to 8 mg, Rb 2 8 to 9.5 mg, Rb 3 1.8 to 2.2 mg , Rd 3.5 to 4.5 mg, Rg 3 0.5 mg, Rh 2 0.01 mg,
b) The vitamin component is 5 to 10% by weight of vitamin B 1 , 2 to 2% by weight, vitamin C 25% by weight, niacin 2% by weight, pantothenic acid 22 to 27% by weight biotin 0.04% by weight and folic acid 0.01 Formulated in weight percent,
c) The mineral component is composed of 1 to 10.5% by weight of magnesium stearate, 1 to 2.5% by weight of selenium, 0.3 to 0.5% by weight of reduced iron, 0.005 to 0.01% by weight of potassium iodide, and 0.3 to 0.5% by weight of manganese sulfate Antistress, antihyperlipidemia and anti-obesity composition characterized in that it is.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130037319A KR101343819B1 (en) | 2013-04-05 | 2013-04-05 | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130037319A KR101343819B1 (en) | 2013-04-05 | 2013-04-05 | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101343819B1 true KR101343819B1 (en) | 2013-12-20 |
Family
ID=49988836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130037319A KR101343819B1 (en) | 2013-04-05 | 2013-04-05 | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101343819B1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101633428B1 (en) | 2016-01-14 | 2016-06-27 | 주식회사 진산사이언스 | Manufacturing Method for Power of Red Ginseng or Ginseng Extract |
| WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
| WO2017057891A1 (en) * | 2015-09-30 | 2017-04-06 | 주식회사 아모레퍼시픽 | Composition for prevention of gray hair |
| KR20190063080A (en) * | 2017-11-29 | 2019-06-07 | 고려인삼연구 주식회사 | Red ginseng extranct improving a decreased immunomodulating ability and method for preparing the same |
| KR20210143037A (en) | 2020-05-19 | 2021-11-26 | 주식회사 동진제약 | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
| KR20210143036A (en) | 2020-05-19 | 2021-11-26 | 주식회사 동진제약 | Fermented red ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
| KR20220058697A (en) * | 2020-10-29 | 2022-05-10 | 주식회사 우리식품 | Method for manufacturing red ginseng snack and red ginseng snack manufactured thereby |
| CN116019819A (en) * | 2022-12-20 | 2023-04-28 | 浙江大学 | Active ginsenoside composition and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100211718B1 (en) | 1997-04-04 | 1999-08-02 | 박명규 | A processing for preparing an anabolic ginseng and its products |
| KR100549193B1 (en) | 2002-10-23 | 2006-02-02 | (주)바이오뉴트리젠 | Foods comprising ginseng and powders or extracts of plants comprising polyphenol or bioflavonoid for suppressing the fatness |
| KR100706111B1 (en) * | 2005-07-12 | 2007-04-12 | 고성권 | A ginseng preparation using vitamin c and process for thereof |
-
2013
- 2013-04-05 KR KR1020130037319A patent/KR101343819B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100211718B1 (en) | 1997-04-04 | 1999-08-02 | 박명규 | A processing for preparing an anabolic ginseng and its products |
| KR100549193B1 (en) | 2002-10-23 | 2006-02-02 | (주)바이오뉴트리젠 | Foods comprising ginseng and powders or extracts of plants comprising polyphenol or bioflavonoid for suppressing the fatness |
| KR100706111B1 (en) * | 2005-07-12 | 2007-04-12 | 고성권 | A ginseng preparation using vitamin c and process for thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
| US11975037B2 (en) | 2015-02-13 | 2024-05-07 | Amorepacific Corporation | Composition for preventing, alleviating or treating burnout syndrome |
| WO2017057891A1 (en) * | 2015-09-30 | 2017-04-06 | 주식회사 아모레퍼시픽 | Composition for prevention of gray hair |
| KR101633428B1 (en) | 2016-01-14 | 2016-06-27 | 주식회사 진산사이언스 | Manufacturing Method for Power of Red Ginseng or Ginseng Extract |
| KR20190063080A (en) * | 2017-11-29 | 2019-06-07 | 고려인삼연구 주식회사 | Red ginseng extranct improving a decreased immunomodulating ability and method for preparing the same |
| KR102129005B1 (en) * | 2017-11-29 | 2020-07-02 | 고려인삼연구 주식회사 | Red ginseng extranct improving a decreased immunomodulating ability and method for preparing the same |
| KR20210143037A (en) | 2020-05-19 | 2021-11-26 | 주식회사 동진제약 | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
| KR20210143036A (en) | 2020-05-19 | 2021-11-26 | 주식회사 동진제약 | Fermented red ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
| KR20220058697A (en) * | 2020-10-29 | 2022-05-10 | 주식회사 우리식품 | Method for manufacturing red ginseng snack and red ginseng snack manufactured thereby |
| KR102517875B1 (en) * | 2020-10-29 | 2023-04-05 | 주식회사 우리식품 | Method for manufacturing red ginseng snack and red ginseng snack manufactured thereby |
| CN116019819A (en) * | 2022-12-20 | 2023-04-28 | 浙江大学 | Active ginsenoside composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101343819B1 (en) | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food | |
| JP2023538664A (en) | Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects | |
| US9167841B2 (en) | Tangerine peel extract and its preparation and application | |
| US10624942B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| US8394431B2 (en) | Composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid | |
| CN109123612A (en) | A kind of composition with strengthen immunity, health food and preparation method thereof | |
| CN108497498A (en) | A kind of functional food of relieving alcoholism and protecting liver and preparation method thereof | |
| WO2013087023A1 (en) | Natural weight reduction health composition and application thereof | |
| KR20130115949A (en) | Pharmaceutical composition with enhanced antioxidant activity comprising the extract of aged ginger | |
| KR20130115945A (en) | Composition comprising the extract of aged ginger for preventing and treating liver disease | |
| CN103181940B (en) | Liver protection tablet with delicious taste used for pets | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN107998269B (en) | A Chinese medicinal composition with effects of lowering blood pressure and blood lipid, and preventing and treating cardiovascular and cerebrovascular diseases | |
| CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
| US20180169071A1 (en) | Nutritional supplement composition | |
| JP2010030950A (en) | Prophylactic and therapeutic agent for metabolic syndrome and functional food | |
| CN103735621A (en) | Chinese medicinal composition with blood lipid reducing and immunity enhancing effects | |
| CN104940666B (en) | A kind of natural drug composition and preparation method with resisting oxygen lack | |
| CN103877513B (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| AU2015266075B2 (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN108142926A (en) | Lotus wheat drinks health care particle | |
| KR20170122612A (en) | Composition and its manufacturing method for sports nutrition comprising of Trigonella foenum-graecum extract and ferulic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20171218 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20181217 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20191216 Year of fee payment: 7 |